MedPath

Onderzoek naar de kosten en werkzaamheid van injectiekuren (immunotherapie) bij patiënten met een allergie voor boompollen, graspollen en/of huisstofmijt.

Recruiting
Conditions
EN:allergic rhinitisimmunotherapyadultcosts and cost analysesNL:allergische rhinitisimmunotherapievolwassenenkosten-effectiviteit
Registration Number
NL-OMON25681
Lead Sponsor
Erasmus MC
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
240
Inclusion Criteria

1. 18-45 years;

2. Clinically relevant moderate to severe allergic rhinitis due to a sensitization for one, two or three of the following
allergens: tree pollen (TP), grass pollen (GP) and/or house dust mite (HDM). For each allergen (TP, GP, HDM) the following 3 criteria are evaluated. A sensitization for an allergen is considered clinically relevant and the rhinitis moderate-severe if:

Exclusion Criteria

1. Severe/instable asthma:

A. FEV1 <70% predicted and/or FEV1/FVC <70;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath